Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tenghui Ma

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Cancer Management and Research|September 1, 2021
Risk Prediction and Treatment of LE-DVT in Patients with Chronic Radiation Intestinal Injury: A Retrospective Case-Control StudyXiaoyan Huang, Yingyi Kuang, Qiyuan Qin, et al.
Science Translational Medicine|February 25, 2021
Platelet-derived growth factor C signaling is a potential therapeutic target for radiation proctopathyWeisi Lu, Yunling Xie, Binjie Huang, et al.
Gastroenterology|August 25, 2023
Development and Validation of a Post-Radiotherapy Prediction Model for Bowel Dysfunction After Rectal Cancer ResectionQiyuan Qin, Binjie Huang, Aiwen Wu, et al.
Digestive Diseases and Sciences|June 15, 2014
Molecular mechanism of acute radiation enteritis revealed using proteomics and biological signaling network analysis in ratsShunxin Song, Dianke Chen, Tenghui Ma, et al.
The Journal of Pathology|November 14, 2022
CXCL16 inhibits epithelial regeneration and promotes fibrosis during the progression of radiation enteritisYanmei Cui, Haiyong Wu, Zhihang Liu, et al.
Annals of Translational Medicine|March 14, 2022
mFOLFOXIRI with or without bevacizumab for conversion therapy of <i>RAS/BRAF/PIK3CA</i> mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trialCailu Shen, Huabin Hu, Yue Cai, et al.
The Oncologist|January 5, 2021
Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II TrialHuabin Hu, Kun Wang, Meijin Huang, et al.
The Lancet. Gastroenterology & Hepatology|October 24, 2021
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trialHuabin Hu, Liang Kang, Jianwei Zhang, et al.
International Journal of Surgery (London, England)|February 13, 2024
Evaluation of transrectal ultrasound-guided tru-cut biopsy as a complementary method for predicting pathological complete response in rectal cancer after neoadjuvant treatment: a phase II prospective and diagnostic trialYaoyi Huang, Yumo Xie, Puning Wang, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Cancer Management and Research|September 1, 2021
Risk Prediction and Treatment of LE-DVT in Patients with Chronic Radiation Intestinal Injury: A Retrospective Case-Control StudyXiaoyan Huang, Yingyi Kuang, Qiyuan Qin, et al.
Science Translational Medicine|February 25, 2021
Platelet-derived growth factor C signaling is a potential therapeutic target for radiation proctopathyWeisi Lu, Yunling Xie, Binjie Huang, et al.
Gastroenterology|August 25, 2023
Development and Validation of a Post-Radiotherapy Prediction Model for Bowel Dysfunction After Rectal Cancer ResectionQiyuan Qin, Binjie Huang, Aiwen Wu, et al.
Digestive Diseases and Sciences|June 15, 2014
Molecular mechanism of acute radiation enteritis revealed using proteomics and biological signaling network analysis in ratsShunxin Song, Dianke Chen, Tenghui Ma, et al.
The Journal of Pathology|November 14, 2022
CXCL16 inhibits epithelial regeneration and promotes fibrosis during the progression of radiation enteritisYanmei Cui, Haiyong Wu, Zhihang Liu, et al.
Annals of Translational Medicine|March 14, 2022
mFOLFOXIRI with or without bevacizumab for conversion therapy of <i>RAS/BRAF/PIK3CA</i> mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trialCailu Shen, Huabin Hu, Yue Cai, et al.
The Oncologist|January 5, 2021
Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II TrialHuabin Hu, Kun Wang, Meijin Huang, et al.
The Lancet. Gastroenterology & Hepatology|October 24, 2021
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trialHuabin Hu, Liang Kang, Jianwei Zhang, et al.
International Journal of Surgery (London, England)|February 13, 2024
Evaluation of transrectal ultrasound-guided tru-cut biopsy as a complementary method for predicting pathological complete response in rectal cancer after neoadjuvant treatment: a phase II prospective and diagnostic trialYaoyi Huang, Yumo Xie, Puning Wang, et al.
Pageof 3